Orchid Pharma Ltd

Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.

Orchid Pharma Ltd trades at ₹1,041, in a confirmed uptrend and 5 weeks into that stage. That is +32.9% against its own 200-day average. It sits at 100% of a 52-week range of ₹502 to ₹1,041. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 17 straight weeks.

Today the stock is in a confirmed uptrend — week 5 of stage 2, confirmed. At ₹1,041 it trades +32.9% versus its 200-day average and sits at 100% of its 52-week range (₹502–₹1,041).

Against the market, two honest reads. Cumulative: over the last 10.3 years the stock moved +2,622% while the NIFTY 500 moved +274% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 17 straight weeks — the ribbon below is that same metric, week by week.

What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.

→ The trend is one thing; the bill is another. Are you paying up for it? Next: the P/E sits at the 98th percentile of its own range.

Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.

Orchid Pharma Ltd trades at 185.0× P/E, about the priciest it has ever traded. Its long-run median P/E is 62.1×, measured across 3.2 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.

Today's P/E of 185.0× is about the priciest it has ever traded, against a long-run median of 62.1× measured over 3.2 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.

🚨 Why the multiple sits where it does: over the past year annual EPS moved −79.4% against a +42.2% price move — the price outran earnings, pushing the multiple UP its own range.

The price move, decomposed: over 3y, of the +25.3%/yr price move, ~+16.3%/yr came from earnings growth and ~+9.0 pp from the multiple (expanding). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.

Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.

→ Cheap or dear rides on the earnings. Are they actually growing? Next: the fundamental stage — where the business sits in its arc, and how growth has compounded.

Stage: Deteriorating Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).

Orchid Pharma Ltd reads as deteriorating on its fundamental arc. Deteriorating — revenue, profit and EPS growth are shrinking (revenue growth −11.8% latest against +28.2% at its 12-quarter best), ROCE slipping at 2.3%. The read is built from 12 quarters across 4 curves, on full evidence.

🚨 Why it matters: falling curves mean every cheap-looking ratio below needs a discount for direction.

→ The stage names the trajectory. Next: the revenue line that produces it, quarter by quarter.

4-Factor Sector Score

23.2/100 — rank 14 of 14 in Pharma - API · 90% evidence confidence

Orchid Pharma Ltd scores 23.2 out of 100 against the 14 companies it is compared with in Pharma - API, ranking 14. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.

The four contributions add to the total exactly: 6.1 + 6.4 + 2.7 + 8 = 23.2. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.

What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.

Revenue Revenue is the top line: everything the company billed its customers in the period.

Orchid Pharma Ltd reported ₹238 Cr of revenue in the Mar 26 quarter, +0.4% year on year. Over 10 years it has compounded at −0.7% a year. The last full year, FY26, came in at ₹811 Cr. The last four reported quarters add to ₹812 Cr.

Orchid Pharma Ltd reported ₹238 Cr of revenue in the Mar 26 quarter, +0.4% year on year. Over 10 years it has compounded at −0.7% a year. The last full year, FY26, came in at ₹811 Cr. The last four reported quarters add to ₹812 Cr.

FY26 revenue came in at ₹811 Cr (−12.0% on the year), capping 10 years at −0.7% compound. The latest quarter (Mar 26) printed ₹238 Cr, +0.4% year on year.

Pace check: the last four quarters averaged −11.6% growth against the decade's −0.7% — the current year is running slower than its own long-run rate.

Acceleration check: trailing-twelve-month revenue grew −11.8% over the last 4 quarters against −0.5%/yr over the last 8 — rolling over; TTM profit −79.8% vs −53.1%/yr — rolling over.

→ Revenue grew — did margins hold as it scaled? Next: 11.0% this quarter (−1.0 pp YoY).

Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.

Orchid Pharma Ltd's operating margin is 11.0% in the Mar 26 quarter, −1.0 percentage points against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged −6.0% to 20.0%. The current quarter sits inside that band.

Orchid Pharma Ltd's operating margin is 11.0% in the Mar 26 quarter, −1.0 percentage points against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged −6.0% to 20.0%. The current quarter sits inside that band.

The latest quarter's operating margin is 11.0%, −1.0 pp against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged −6.0%–20.0%.

🚨 Why the margin moved: operating margin went −0.5 pp year on year while gross margin went −5.6 pp — the loss came mostly from the gross line: input costs and pricing.

→ Margins slipped — did that reach the bottom line? Next: profit +9.1% in the latest quarter.

Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.

Orchid Pharma Ltd earned ₹24.0 Cr of net profit in the Mar 26 quarter, +9.1% year on year. Full-year FY26 profit was ₹21.0 Cr. That is 10.1% of the quarter's revenue. The same quarter a year earlier earned ₹22.0 Cr. 2 of the last 12 reported quarters were loss-making.

Orchid Pharma Ltd earned ₹24.0 Cr of net profit in the Mar 26 quarter, +9.1% year on year. Full-year FY26 profit was ₹21.0 Cr. That is 10.1% of the quarter's revenue. The same quarter a year earlier earned ₹22.0 Cr. 2 of the last 12 reported quarters were loss-making.

Mar 26 profit was ₹24.0 Cr, +9.1% year on year. On the full year, FY26 printed ₹21.0 Cr (−79.0%).

Why profit moved: revenue contributed +0.4% and the margin −1.0 pp — the quarter was revenue-led, with the margin roughly flat.

Pace comparison, last four quarters: profit −80.8% vs revenue −11.6%. Profit is growing slower than sales — costs are eating the growth before it reaches the bottom line.

→ Profit rose — but did the cash follow? Next: 115% of the last 3 years' profit arrived as cash.

Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.

Over the last 3 fiscal years 115% of Orchid Pharma Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹101 Cr of operating cash against ₹21.0 Cr of profit. After ₹354 Cr of capital spending, ₹−253 Cr was left as free cash.

FY26: operating cash of ₹101 Cr against reported profit of ₹21.0 Cr, leaving free cash of ₹−253 Cr after ₹354 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 115% of profit.

Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.

Why conversion sits at 115%: the cash cycle tightened 42 days between FY21 and FY26 — cash that used to wait in the cycle now reaches the bank sooner.

Router verdict: the bigger cash user is investment — capital spending ran 5.0× depreciation over three years, so the next section's job is to check what that build-out is buying.

→ So follow the cash to where it goes. Next: ₹517 Cr of building over 3 years.

Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).

Orchid Pharma Ltd's cash conversion cycle runs 137 days in FY26, down from 179 days in FY21. Capital spending ran ₹517 Cr over the last 3 years. At FY26 sales of ₹811 Cr each day of that cycle holds about ₹2.2 Cr, so roughly ₹304 Cr sits inside the business at any moment.

FY26: debtors at 119 days, inventory at 178 days — roughly 5.9 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 137 days, tighter than FY21's 179.

The full loop: cash goes out to suppliers and production on day 0; stock waits 178 days to sell; customers pay about 119 days after that; and suppliers themselves are paid at 160 days — netting out to the 137-day cycle.

In money terms: at FY26 sales of ₹811 Cr, each day of the cycle holds about ₹2.2 Cr — so the 137-day loop keeps roughly ₹304 Cr sitting inside the business at any moment.

On the investment side: capital spending of ₹517 Cr over the last 3 fiscal years against ₹103 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹341 Cr (FY26) — capacity paid for but not yet earning.

The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.

→ Does all this activity actually earn its cost of capital? Next: ROCE is 3% and the ROIC − WACC spread is −11.6 pp.

Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.

Orchid Pharma Ltd earns a ROCE of 3% in FY26. That is up from a trough of −6% in FY20. Return on invested capital clears the cost of that capital by −11.6 percentage points, so growth here is not yet paying for the capital it uses. The wiring behind it is 2.6% net margin on 0.42× asset turns.

FY26 ROCE is 3%, recovered from a FY20 trough of −6% — the full ladder below shows the fall and the climb, undoctored.

🚨 Why the return is what it is — the wiring (FY26): 2.6% net margin × 0.42× asset turns × 1.48× balance-sheet leverage ≈ 1.6% on equity. Margin does its share; leverage is modest — this is an earned return, not a borrowed one.

The capstone test — ROIC − WACC: 0.4% − 12.0% = a −11.6 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. Negative — growth at these returns destroys value until the returns recover.

→ Returns like these — is the balance sheet borrowing to make them? Next: debt-to-equity is 0.28.

Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.

Orchid Pharma Ltd carries total debt of ₹363 Cr against shareholder equity of ₹1,288 Cr as of Mar 26, a debt-to-equity of 0.28 — effectively unlevered. On the annual view that ratio went from 0.41 in FY22 to 0.28 in FY26. The returns elsewhere on this page are therefore earned rather than borrowed.

Mar 26: total debt of ₹363 Cr against shareholder equity of ₹1,288 Cr — a debt-to-equity of 0.28. On the annual view, debt-to-equity went from 0.41 (FY22) to 0.28 (FY26). The returns on this page are earned, not borrowed.

→ Who owns this, and are they adding or leaving? Next: Domestic institutions added 1.8 points over 8 quarters.

Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.

Domestic institutions added 1.8 points of Orchid Pharma Ltd over 8 quarters, the biggest move on the register. That takes domestic institutions to 20.8% of the company. Foreign institutions moved −0.6 points over the same window, to 0.8%. The register is read on the four disclosed classes only; nothing is inferred between filings.

The register over the last two years — Domestic institutions: +1.8 points over 8 quarters to 20.8%; Foreign institutions: −0.6 points over 8 quarters to 0.8%; Promoters: +0.0 points over 8 quarters to 69.8%.

Why the register moved: domestic institutions drove it (+1.8 points), absorbed on the other side by foreign institutions (−0.6 points) — steady accumulation by institutions reading the same numbers this page reads.

→ One last check: does the safety math agree? Next: the balance-sheet safety line.

Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.

Orchid Pharma Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.

The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.

Frequently asked questions